Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 1
2017 1
2018 2
2019 1
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N, Blanco A, Madden SF, Moran B, Fletcher JM, Kaukonen D, Ramírez JS, Eustace AJ, McDermott MSJ, Canonici A, Toomey S, Teiserskiene A, Hennessy BT, O'Donovan N, Crown J, Collins DM. Gaynor N, et al. Among authors: ramirez js. Br J Cancer. 2023 Oct;129(6):1022-1031. doi: 10.1038/s41416-023-02375-y. Epub 2023 Jul 28. Br J Cancer. 2023. PMID: 37507543 Free PMC article. Clinical Trial.
Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF.
Sánchez Ramírez J, Morera Díaz Y, Musacchio Lasa A, Bequet-Romero M, Muñoz Pozo Y, Pérez Sánchez L, Hernández-Bernal F, Mendoza Fuentes O, Selman-Housein KH, Gavilondo Cowley JV, Ayala Avila M. Sánchez Ramírez J, et al. J Immunoassay Immunochem. 2016;37(6):636-58. doi: 10.1080/15321819.2016.1184164. J Immunoassay Immunochem. 2016. PMID: 27143151
Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Martín Bauta Y, Selman-Housein Bernal KH, de la Torre Santos AV, Pérez de la Iglesia M, Trimiño Lorenzo L; Team of Investigators of Compassionate use Program; Ayala Avila M. Sánchez Ramírez J, et al. BMC Immunol. 2020 Mar 14;21(1):12. doi: 10.1186/s12865-020-0338-4. BMC Immunol. 2020. PMID: 32171254 Free PMC article.
Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors.
Sánchez Ramírez J, Bequet-Romero M, Morera Díaz Y, Hernández-Bernal F, de la Torre Santos A, Selman-Housein Bernal KH, Martín Bauta Y, Bermúdez Badell CH, Limonta Fernández M, Ayala Avila M. Sánchez Ramírez J, et al. Heliyon. 2018 Nov 2;4(11):e00906. doi: 10.1016/j.heliyon.2018.e00906. eCollection 2018 Nov. Heliyon. 2018. PMID: 30426104 Free PMC article.
Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Selman-Housein Bernal KH, de la Torre Santos A, Santiesteban Álvarez ER, Martín Bauta Y, Bermúdez Badell CH, de la Torre Pupo J, Gavilondo JV; CENTAURO-2 Team of Investigators; Ayala Avila M. Sánchez Ramírez J, et al. BMC Immunol. 2017 Jul 26;18(1):39. doi: 10.1186/s12865-017-0222-z. BMC Immunol. 2017. PMID: 28747172 Free PMC article. Clinical Trial.